| Abstract: | Vemurafenib, a selective BRAF kinase inhibitor, has been found to induce several cutaneous adverse effects, ranging from a keratosis pilaris‐like reaction to squamous cell carcinoma. While photosensitivity has been well described as one of these manifestations, we report a case of a 6‐year‐old boy on vemurafenib who developed a severe blistering sunburn after only two 30‐minute episodes of sun exposure. A brief review of other common cutaneous adverse effects of vemurafenib is also provided. |
